Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Aug;17(9):1736-1743.e4.
doi: 10.1016/j.cgh.2018.12.032. Epub 2019 Jan 4.

Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis

Nienke Z Borren  1 , Ashwin N Ananthakrishnan  2
Affiliations
Meta-Analysis

Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis

Nienke Z Borren et al. Clin Gastroenterol Hepatol. 2019 Aug.

Abstract

Background & aims: Management of immune-mediated inflammatory diseases often requires lifelong immunosuppression. Increasing numbers of older patients have inflammatory diseases and are particularly vulnerable to risks of immune suppressive therapies-particularly infections and malignancies.

Methods: We systematically searched PubMed/Medline and Embase to identify eligible studies that examined the safety of biologic therapies in older patients with immune-mediated inflammatory diseases (inflammatory bowel disease, rheumatoid arthritis, psoriasis). Included studies provided information on patients who began receiving therapy with a biologic agent when they were older than 60 years and a control population (either younger users of biologics or older patients who did not use biologics). Information of on overall pooled rates of infections, malignancy, and mortality were extracted. A DerSimonian and Laird random effects model was used to calculate pooled odds ratios (ORs) and 95% CIs.

Results: Our meta-analysis included 14 unique studies that comprised 4719 older users of biologics, 13,305 younger users of biologics, and 3961 older patients who did not use biologics. The pooled prevalence of infections in older and younger users of biologics was 13% and 6% respectively, yielding a pooled random effects odds ratio of 2.28 (95% CI, 1.57-3.31). Older age was associated with a significant increase in risk of malignancy (OR, 3.07; 95% CI, 1.98-4.62) compared to younger age. Older users of biologics had a 3-fold increase in risk of infection compared to patients who did not use biologics (OR, 3.60; 95% CI, 1.62-8.01), but there were no significant differences in odds of malignancy (0.54, 95% CI, 0.28-1.05) or death (OR, 1.52; 95% CI, 0.44-5.28) compared to older patients who did not use biologics.

Conclusion: In a systematic review and meta-analysis of studies on the safety of biologic therapies in older patients with inflammatory diseases, we found that older users of biologic agents have an increased risk of infections compared with younger users or older patients who do not use biologics. Large, prospective cohort studies are needed to examine safety of biologic therapy in older patients with immune-mediated diseases.

Keywords: Anti-TNF Therapy; Autoimmune Disease; Drug; Elderly; IBD; Inflammatory Bowel Disease; Psoriasis; Rheumatoid Arthritis; Safety; Tumor Necrosis Factor.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Flow chart of the literature search
Figure 2:
Figure 2:
Forest plot of pooled infection risk among older patients with an IMD on biologic therapy compared to controls; 2a: Older biologic users compared to younger biologic users Figure 2: Forest plot of pooled infection risk among older patients with an IMD on biologic therapy compared to controls; 2b: Older biologic users compared to older non-users
Figure 2:
Figure 2:
Forest plot of pooled infection risk among older patients with an IMD on biologic therapy compared to controls; 2a: Older biologic users compared to younger biologic users Figure 2: Forest plot of pooled infection risk among older patients with an IMD on biologic therapy compared to controls; 2b: Older biologic users compared to older non-users
See this image and copyright information in PMC

References

    1. Dhingra R, Vasan RS. Age as a risk factor. Med Clin North Am 2012;96:87–91. - PMC - PubMed
    1. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States. Atlanta, Georgia, US: Centers for Disease Control and Prevention, 2011.
    1. US cancer statistics: 1999 – 2009 incidence and mortality web-based report. Volume http://www.cdc.gov/uscs. Atlanta, Georgia: U.S. Cancer Statistics Working Group, 2013.
    1. Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 2004;57:6–14. - PMC - PubMed
    1. Siegel CA, Hur C, Korzenik JR, et al. Risks and benefits of infliximab for the treatment of Crohn’s disease. Clin Gastroenterol Hepatol 2006;4:1017–24; quiz 976. - PubMed

MeSH terms